Attovia Therapeutics, Inc. (ATTO)

NASDAQ: ATTO · Real-Time Price · USD

13.83

-0.67 (-4.62%)

Oct 23, 2026, 4:00 PM EDT - Market closed

Attovia Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	1.8	1.35	-
Revenue Growth	-	-	-
Gross Profit	-62.46	-52.8	-33.86
Operating Income	-76.19	-67.16	-41.55
Net Income	-70.11	-60.63	-39.8
Earnings Per Share	-17.01	-15.35	-11.27
EPS Growth	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Investments	115.13	152.27	69.32
Total Debt	4.33	5.26	-
Net Cash (Debt)	110.81	147.01	69.32
Net Cash Growth	-	112.06%	-
Net Cash Per Share	26.88	37.22	19.63

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Cash Flow	-67.43	-59.2	-35.04
Capital Expenditures	-0.79	-2.31	-1.77
Free Cash Flow	-68.22	-61.51	-36.81
Free Cash Flow Growth	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Margin	-4232.94%	-4974.74%	-
Pretax Margin	-3910.00%	-4490.89%	-
Profit Margin	-3894.94%	-4490.89%	-
FCF Margin	-3790.11%	-4556.44%	-